Abstract:Objective To observe the inhibitory effect and mechanism of 9-nitrocamptothecin liposomes on HepG2 liver carcinoma cells. Methods HepG2 cells were incubated with 9-nitrocampto-thecin(9NC) or with 9-nitrocamptothecin liposomes(9NC-LP) for 24 h, 48 h and 72 h. Cell viability was then measured by the MTT assay. Cell cycle and apoptosis were evaluated by flow cytometry.Western Blot was used to determine the expression of cell cycle and apoptosis related proteins. HepG2tumor-bearing mouse models were then established. The HepG2 tumor-bearing mice were randomly divided into control group, free liposomes group, DMSO group, 9NC low dose group, 9NC high dose group, 9NC-LP low dose group and 9NC-LP high dose group. There were 10 mice in each group.Drugs were administered by tail vein and tumor volume and body weight were observed 28 days after administration. Then animals were sacrificed and the expression of proteins from tumor homogenates was analyzed by Western blotting. Results In vitro, HepG2 cell viability was apparently inhibited by 9NC and 9NC-LP, and the inhibitory effect increased in a time-dependent and dose-dependent manner.Both S and G2/M phase arrests were observed after incubation with drugs. HepG2 cells were completely arrested in S phase with 9NC concentration over than 0.1 μmol/L after incubation for 24 h,while more than 95% of cells arrested in G2/M phase when 9NC concentration was 0.1 μmol/L after incubation for 72 h. In vivo, compared with the control group, the average tumor volume was reduced in both the 9NC and 9NC-LP group (P<0.05) , and the average animal body weight also decreased in both the 9NC and 9NC-LP group (P<0.05). There was no significant difference among the control group, free liposomes group, and DMSO group. The lights inhibition rates of tumor growth in the 9NC-LP(2.5 mg/kg),9NC-LP(1.5 mg/kg),and 9NC(1.5 mg/kg)groups were 87.02%, 51.57%and 35.47%, respectively. In the 9NC-LP(2.5 mg/kg)group, >50% of animals died 14 days after drug administration. Conclusion 9NC and 9NC-LP can inhibit HepG2 cell growth via cell cycle arrest and apoptosis induction. 9NC-LP has a more potent anti-tumor effect and fewer side effects in vivo,which means 9NC-LP is a promising compound for cancer therapy via intravenous administration.

Pharmacokinetics and Tissue Distribution in Tumor-bearing Mice After iv Administration of 9-Nitrocamptothecin with Different Lactone Ratios

Pharmacokinetics Of Lactone, Carboxylate And Total 9-Nitrocamptothecin With Different Doses And Administration Routes In Rats

Tissue Distribution and Lactone Stability of 9-Nitrocamptothecin in Rats

Lactone Stability and Tissue Distribution of Free and Liposomal Encapsulated 9-Nitrocamptothecin in Rats Following Intravenous Injection

Pharmacokinetics of 9-Nitrocamptothecin Liposomes in Rats after Intravenous Administration

Pharmacokinetics and Urinary Excretion of 9-Nitrocamptothecin Following Intravenous Administration of Lactone and Carboxylate Forms to Rats

Effect of Injection Routes on Pharmacokinetics and Lactone/carboxylate Equilibrium of 9-Nitrocamptothecin in Rats.

[In Vitro and in Vivo Stability of 9-Nitrocamptothecin Lactone Form in Rats].

Pharmacokinetics of 9-Nitrocamptothecin after Single Oral Administrations in Rats

In vitro and in vivo inhibitory effects and mechanism of 9-nitrocamptothecin liposomes on HepG2 cell

Biodistribution in Mice and Severity of Damage in Rat Lungs Following Pulmonary Delivery of 9-Nitrocamptothecin Liposomes

Effect of Tween80 on the Pharmacokinetics of 9-nitrocamptothecin Liposome

Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation.

Characterization of 9-Nitrocamptothecin Liposomes: Anticancer Properties and Mechanisms on Hepatocellular Carcinoma in Vitro and in Vivo

Effect of Copolymer Micelles on Lactone Stability of 9-Nitro-20(s)-camptothecin

Pharmacodynamics Study of Hydroxycamptothecin on Mice Models of H22

Pharmacokinetics of 9-Nitrocamptothecin Capsule in Patients .with Advanced Solid Tumors

Preparation of 9-Nitrocamptothecin Liposome and Its Pharmacokinetic after Pulmonary Delivery to Rats

Distribution of 9-nitro-20(S)-camptothecin loaded micelles in the blood and organs of rats

Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in the rat.

Biliary Excretion of 9-Nitrocamptothecin after Intravenous Administration of 9-Nitrocamptothecin Liposome to Rats